MYO19

Across TCGA pan-cancer cohorts, MYO19 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO19 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MYO19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO19 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LIHC, SKCM, and PRAD are the cancer types where MYO19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
SKCM	DFS	Median	All	0.808	0.199	.011	7	view →
PRAD	DFS	Median	All	0.085	0.774	.009	6	view →
UCEC	DFS	Median	All	0.915	0.609	.018	4	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYO19–LIHC (OS)

Open the LIHC breakdown →